Technical Description
This invention presents an advanced solid dispersion formulation of dabigatran that aims to improve pharmacokinetics and pharmacodynamics for the purpose of treating stroke disorders successfully.
Problems Addressed
- Low Oral bioavailability
- Poor water solubility
- Increased risk of bleeding
- Complexities in PEG inhibition
- Inter-individual variability challenges
- Issues with pharmacokinetic profiles
Tech Features
- Enhanced Bioavailability
- Improved Solubility
- Stabilized Pharmacokinetics
- Reduced Bleeding Risk & Daily Dose
- Minimized Inter-individual Variability
Target Audience
- Pharmaceutical Industry
- Research Institutions
- Healthcare Providers
- Regulatory Agencies
Tech ID: P27-1134 TRL 4 Patent Status: Granted Available For Exclusive and Non-exclusive License
